CNID Demographics

Chronic nasal inflammatory diseases (CNID) represent an important underserved medical need and large market opportunity. These chronic inflammatory conditions of the nasal passages affect as many as 40-50 million adults in the United States, half of whom have been diagnosed. Roughly 10 million people in the U.S. alone are affected enough that they have undergone nasal/sinus surgery to try and reduce their symptoms, with more than 500,000 surgeries performed every year[1]. Approximately 20 percent of chronic sinusitis patients and 1-2 percent of allergic rhinitis patients develop nasal polyps, benign growths in the lining of the nose that can block nasal passages and interfere with breathing.

Few Available Options

There are no currently approved medications in the U.S. or Europe for the treatment of chronic sinusitus, and only one is approved for the treatment of nasal polyps. For both conditions, the only new treatments in development other than OptiNose’s OPN-375 (a device using the innovative OptiNose mechanism that delivers fluticasone) are complex and expensive monoclonal antibody injections.

Chronic sinusitus sufferers use multiple acute and chronic prescription and non-prescription treatment modalities, including nasal, oral and injected steroids; antibiotics; antifungal treatments; topical and oral decongestants; locally compounded steroid-containing lavages; and saline irrigation such as with a Neti pot. This is often burdensome, complex, time-consuming, and expensive. Despite the fact that almost all patients use chronic medication, many do not achieve satisfactory relief. Even patients who progress to surgery may have limited success, often undergoing multiple procedures and usually continuing to use medication after the procedure.

OPN-375 is a new approach, currently in phase III clinical trials to evaluate its efficacy and safety in treating patients suffering from chronic sinusitus with or without nasal polyps.


[1] Bhattacharyya, N., Laryngoscope. 2010 Mar;120(3):635-8. doi: 10.1002/lary.20777.